Laidlaw & Company

On Monday, Mast Therapeutics Inc (NYSE: MSTX) provided an update on its business strategy and the clinical development of its product candidate AIR001. Laidlaw’s Yale Jen maintains a Neutral rating on the company. Update “Management reiterated that MSTX will focus on clinical...

Laidlaw’s Jim Molloy believes Gemphire Therapeutics Inc’s (NASDAQ: GEMP) lead product candidate, Gemcabene, has the potential to become one of the most interesting entrants to the cardiovascular disease (CVD) space, with “true blockbuster potential.” Molloy initiated...

Headache combatant CoLucid Pharmaceuticals (NASDAQ: CLCD) is three days from going public Friday, May 1. The biopharmaceutical company plans to raise $86 million through 5.4 million shares between $13 and $15. CoLucid has a market cap of $210 million and will list on the NASDAQ under the ticker...